Pre-Open Stock Movers 03/03: (MITO) (INO) (WIFI) Higher; (CODX) (TLRY) (KPTI) Lower (more...)

Today's Pre-Open Stock Movers

Stealth BioTherapeutics (NASDAQ: MITO) 52.6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for elamipretide for the treatment of Barth syndrome, an ultra-rare genetic condition.

Co-Diagnostics (NASDAQ: CODX) 20.3% LOWER; Maxim Group downgraded from Buy to Hold. Coronavirus plays lower.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) 19.4% HIGHER; announced an accelerated timeline for developing its DNA vaccine INO-4800 to address COVID-19, the respiratory infection the World Health Organization (WHO) has designated a Public Health Emergency of International Concern of the highest level. According to WHO, approximately 89,000 cases have been reported globally with more than 3,000 deaths.

Boingo Wireless (NASDAQ: WIFI) 17.7% HIGHER; reported Q4 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $64.06 million versus the consensus estimate of $69.74 million. Also, confirmed it received multiple deal inquiries.

Genworth Financial, Inc. (NYSE: GNW) 16.3% HIGHER; and China Oceanwide Holdings Group Co., Ltd. (Oceanwide) today announced that they have agreed in principle with the New York State Department of Financial Services (NYDFS) on conditions that are expected to facilitate a reapproval by the NYDFS of the proposed acquisition of control by Oceanwide of Genworth's New York-domiciled insurance company, Genworth Life Insurance Company of New York (GLICNY). Genworth has agreed, among other things, to contribute $100 million to GLICNY at the closing of the Oceanwide transaction. The reapproval of the NYDFS remains subject to submission and approval of the documentation setting forth the agreed upon conditions. Oceanwide and Genworth are working to complete this process as soon as possible.

IBIO, INC. (NYSE: IBIO) 15.8% HIGHER; announced that its Board of Directors has decided it will not seek authority from the shareholders at the 2019 Annual Meeting (“Annual Meeting”) to effect a reverse split of its issued and outstanding shares of common stock and, accordingly, Proposal No. 5 in the Definitive Proxy Statement filed with the Securities and Exchange Commission on January 23, 2020 (the “Proxy Statement”) for such authority has been withdrawn from the agenda for the Annual Meeting.

QIAGEN N.V. (NYSE: QGEN) 15.7% HIGHER; Thermo Fisher Scientific Inc. (NYSE: TMO) and QIAGEN N.V. (NYSE: QGEN) announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN for 39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN's common stock on the Frankfurt Prime Standard on March 2, 2020, the last trading day prior to the announcement of the transaction. Thermo Fisher will commence a tender offer to acquire all of the ordinary shares of QIAGEN.

Omeros Corporation (Nasdaq: OMER) 14.8% HIGHER; today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and trial enrollment has been closed. Narsoplimab is Omeros human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2).

GenMark Diagnostics, Inc. (NASDAQ: GNMK) 14% HIGHER; announced the initial shipments of ePlex Research Use Only (RUO) test kits designed to detect the SARS-CoV-2 virus. Initial RUO test kits were recently shipped to the company’s Hong Kong distributor, as well as several U.S. customers that have access to clinical samples. GenMark plans to use this information to support submission of an Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the ePlex SARS-CoV-2 test to address this developing global public health emergency.

International Game Tech (NYSE: IGT) 13.6% HIGHER; reported Q4 EPS of $0.31, $0.07 better than the analyst estimate of $0.24. Revenue for the quarter came in at $1.25 billion versus the consensus estimate of $1.23 billion.

Tilray, Inc. (NASDAQ: TLRY) 11.7% LOWER; reported Q4 EPS of ($0.62), $0.27 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $46.94 million versus the consensus estimate of $55.38 million.

Impinj (NASDAQ: PI) 10% HIGHER; reported Q4 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $40.8 million versus the consensus estimate of $38.1 million. Impinj sees Q1 2020 EPS of ($0.11)-$0.02, versus the consensus of ($0.09). Impinj sees Q1 2020 revenue of $37-41 million, versus the consensus of $36.05 million.

Precigen, Inc. (NASDAQ: PGEN) 7.9% LOWER; reported Q4 EPS of ($0.47), $0.20 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $17 million versus the consensus estimate of $23.4 million.

Tesla (NASDAQ: TSLA) 7.9% HIGHER; JMP Securities upgraded from Market Perform to Market Outperform with a Street High price target of $1,060.00.

Weight Watchers International (NASDAQ: WW) 6.3% HIGHER; Citi upgraded from Neutral to Buy with a price target of $37.00.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) 5.7% LOWER; announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. In addition, Karyopharm also intends to grant the underwriters a 30-day option to purchase up to $22.5 million in shares of its common stock.

Maxar Technologies Ltd. (NYSE: MAXR) 3.9% LOWER; reported Q4 EPS of $0.87, $0.19 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $410 million may not compare versus the consensus estimate of $560.3 million.

eHealth, Inc. (NASDAQ: EHTH) 3.2% LOWER; announced that it intends to offer and sell, subject to market and other conditions, 1,500,000 shares of its common stock in an underwritten public offering pursuant to eHealth's existing shelf registration statement. In connection with this offering, eHealth expects to grant the underwriters a 30-day option to purchase up to 225,000 additional shares of its common stock. eHealth intends to use the net proceeds of the offering for general corporate purposes, including working capital.

Visa (NYSE: V) 1.8% LOWER; sees Q2 revenue growth 2.5%-3.5% lower than previous outlook

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Tarsus Pharmaceuticals (TARS) Refinances Existing Debt with $200M Non-dilutive Financing
• Infinite Reality Acquires the Drone Racing League for $250 Million, Solidifying Position as Global Leader in Immersive Technology & Experiences (NBST)